Overview

• X4 Pharmaceuticals Q3 net loss narrows to $29.8 mln from $36.7 mln yr ago

• Company raised $240.3 mln in financing, extending cash runway to end of 2028

• X4 Pharmaceuticals reports $13 mln annualized cost savings from workforce reduction

Outlook

• X4 expects to complete 4WARD trial enrollment by Q3 2026

• Company's cash runway extends to end of 2028

• X4 plans to launch mavorixafor for chronic neutropenia by end of 2028

• Workforce reduction expected to save $13 mln annually

Result Drivers

• NET LOSS - Net loss for the three months ended September 30, 2025 was $29.8 million, or $0.69 for basic and diluted loss per share, compared to net loss of $36.7 million, or $5.48 for basic and diluted loss per share, for the same period in 2024

• FINANCIAL STRENGTHENING - Raised $240.3 mln in financings, extending cash runway

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for X4 Pharmaceuticals Inc is $9.00, about 55.9% above its November 4 closing price of $3.97

Press Release: ID:nGNX21sz7z

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)